BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37051241)

  • 1. Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab.
    Lin YT; Li CF; Wu HC; Jan YH; Kuo YH
    Front Immunol; 2023; 14():1131448. PubMed ID: 37051241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.
    Iijima Y; Sakakibara R; Ishizuka M; Honda T; Shirai T; Okamoto T; Tateishi T; Sakashita H; Tamaoka M; Takemoto A; Kumaki Y; Ikeda S; Miyazaki Y
    Immunotherapy; 2020 Jun; 12(8):563-569. PubMed ID: 32363992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    PeerJ; 2024; 12():e16923. PubMed ID: 38374950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
    Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
    Mao R; Liu M; Shu X; Li W; Yan W; Li X
    Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
    [No Abstract]   [Full Text] [Related]  

  • 9. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.
    Panozzi M; Alì G; Proietti A; Melfi F; Zirafa CC; Lucchi M; Fontanini G
    Pathologica; 2023 Jun; 115(3):164-171. PubMed ID: 37387441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
    Chatzopoulos K; Boland JM
    Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
    Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
    Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
    Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report.
    Minoshima A; Sugita S; Segawa K; Aoyama T; Ito M; Daimon F; Takenami T; Kido T; Moriya J; Nishikiori H; Hasegawa T
    Diagn Cytopathol; 2023 May; 51(5):E149-E154. PubMed ID: 36772934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
    Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
    Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thoracic
    Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma.
    Ogunbona OB; Lin X; Hornick JL; Lubin DJ; Wang Q; Reid MD; Schneider F; Li D; Shin DM; Shi Q
    J Am Soc Cytopathol; 2022; 11(4):183-193. PubMed ID: 35491322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.
    Tagal V; Wei S; Zhang W; Brekken RA; Posner BA; Peyton M; Girard L; Hwang T; Wheeler DA; Minna JD; White MA; Gazdar AF; Roth MG
    Nat Commun; 2017 Jan; 8():14098. PubMed ID: 28102363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.